839707-37-8 Usage
Description
N-(3-(7-(1,3-dimethyl-1H-pyrazol-5-ylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide is a complex organic compound with a unique molecular structure. It is characterized by the presence of a pyrazol-5-ylamino group, a 1-methyl-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl moiety, and a 4-methylphenyl group attached to a benzamide backbone. The trifluoromethyl group further adds to its structural complexity and potential applications.
Uses
Used in Pharmaceutical Industry:
N-(3-(7-(1,3-dimethyl-1H-pyrazol-5-ylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide is used as a dual inhibitor for extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Its ability to inhibit these proteins makes it a promising candidate for the development of new therapeutic agents targeting various diseases, including cancer.
Used in Stem Cell Research:
In the field of stem cell research, N-(3-(7-(1,3-dimethyl-1H-pyrazol-5-ylamino)-1-methyl-2-oxo-1,2-dihydropyrimido[4,5-d]pyrimidin-3(4H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide, also known as Pluripotin, is used to maintain embryonic stem cell (ESC) self-renewal. Its combination with leukemia inhibitory factor greatly promotes the derivation of embryonic stem cell lines from refractory strains, which is crucial for advancing stem cell-based therapies and regenerative medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 839707-37-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,3,9,7,0 and 7 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 839707-37:
(8*8)+(7*3)+(6*9)+(5*7)+(4*0)+(3*7)+(2*3)+(1*7)=208
208 % 10 = 8
So 839707-37-8 is a valid CAS Registry Number.
839707-37-8Relevant articles and documents
First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia
Cho, Hanna,Shin, Injae,Ju, Eunhye,Choi, Seunghye,Hur, Wooyoung,Kim, Haelee,Hong, Eunmi,Kim, Nam Doo,Choi, Hwan Geun,Gray, Nathanael S.,Sim, Taebo
, p. 8353 - 8383 (2018/09/27)
GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, 10d, 10g, and 11i, which possess single-digit nanomolar inhibitory activity against both ACK1 and GCK. These substances strongly suppress proliferation of mutant NRAS expressing AML cells via apoptosis and AKT/mTOR signaling blockade. Compound 11i is superior to GNF-7 in terms of kinase inhibitory activity, cellular activity, and differential cytotoxicity. Moreover, 10k possessing a favorable mouse pharmacokinetic profile prolonged life-span of Ba/F3-NRAS-G12D injected mice and significantly delayed tumor growth of OCI-AML3 xenograft model without causing the prominent level of toxicity found with GNF-7. Taken together, this study provides insight into the design of novel ACK1 and GCK dual inhibitors for overriding NRAS mutant-driven AML.